FDA Approves Once-Daily Combination Pill to Treat HIV Infection in Treatment-Naive Adults
“The U.S. Food and Drug Administration … approved Stribild (elvitegravir, cobicistat, emtricitabine, tenofovir disoproxil fumarate), a new once-a-day combination pill to treat HIV-1 infection in adults who have never been treated for HIV infection.
“Stribild contains two previously approved HIV drugs plus two new drugs, elvitegravir and cobicistat. Elvitegravir is an HIV integrase strand transfer inhibitor, a drug that interferes with one of the enzymes that HIV needs to multiply. Cobicistat, a pharmacokinetic enhancer, inhibits an enzyme that metabolizes certain HIV drugs and is used to prolong the effect of elvitegravir. The combination of emtricitabine and tenofovir disoproxil fumarate, approved in 2004 and marketed as Truvada, blocks the action of another enzyme that HIV needs to replicate in a person’s body. Together, these drugs provide a complete treatment regimen for HIV infection. …
“Like labels of many other drugs used to treat HIV, Stribild’s label carries a Boxed Warning alerting patients and health care professionals that the drug can cause a build up of lactic acid in the blood and severe liver problems, both of which can be fatal. The Boxed Warning also states that Stribild is not approved to treat chronic hepatitis B virus infection.”
More information is available:
AIDSinfo and infoSIDA News Widgets Are Now Available
AIDSinfo is pleased to announce the release of our news widget! The news widget is available in English and Spanish. Add the AIDSinfo or infoSIDA news widget to your website to display the same information featured in the news feeds on AIDSinfo and infoSIDA. Adding the news widget to your website will provide your site visitors with easy access to the latest HIV/AIDS treatment, prevention, and research news, including announcements from federal agencies and updates from AIDSinfo. Instructions for adding the widget to your website can be found on the AIDSinfo widgets page and the infoSIDA widgets page.